Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 10, 2010, Pages 1463-1466

  Rotta, Marcello ^a   Storer, Barry E ^a   Storb, Rainer ^a   Martin, Paul J ^a   Flowers, Mary E D ^a   Vernon, Miwa S ^a   Peffer, Amanda ^a   Maloney, David G ^a   Deeg, H Joachim ^a   Sandmaier, Brenda M ^a   Appelbaum, Frederick R ^a   Mielcarek, Marco ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Graft versus host disease; GVHD; Statins

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; METHOTREXATE; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK REDUCTION; SIBLING;

ADULT; AGED; CHRONIC DISEASE; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77956271683     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.05.006     Document Type: Article

References (20)

1. Zeiser R., Maas K., Youssef S., Durr C., Steinman L., Negrin R.S. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 2009, 127:18-25.
2. Greenwood J., Steinman L., Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006, 6:358-370.
3. Mausner-Fainberg K., Luboshits G., Mor A., et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008, 197:829-839.
4. Shimabukuro-Vornhagen A., Liebig T., Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood 2008, 112:1544-1545.
5. Blank N., Schiller M., Krienke S., et al. Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol 2007, 179:3613-3621.
6. Fehr T., Kahlert C., Fierz W., et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004, 175:83-90.
7. Zeiser R., Youssef S., Baker J., Kambham N., Steinman L., Negrin R.S. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007, 110:4588-4598.
8. Hamadani M., Awan F.T., Devine S.M. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008, 111:3901-3902.
9. Rotta M., Storer B.E., Storb R.F., et al. Donor-statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood 2010, 115:1288-1295.
10. Broady R., Levings M.K. Graft-versus-host disease: suppression by statins. Nat Med 2008, 14:1155-1156.
11. Wang Y., Li D., Jones D., et al. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:1513-1522.
12. Velho J.A., Okanobo H., Degasperi G.R., et al. Statins induce calcium-dependent mitochondrial permeability transition. Toxicology 2006, 219:124-132.
13. Waldmeier P.C., Zimmermann K., Qian T., Tintelnot-Blomley M., Lemasters J.J. Cyclophilin D as a drug target. Curr Med Chem 2003, 10:1485-1506.
14. Ichimaru N., Takahara S., Kokado Y., et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001, 158:417-423.
15. Lemahieu W.P., Hermann M., Asberg A., et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005, 5:2236-2243.
16. Kalliokoski A., Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009, 158:693-705.
17. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80:565-581.
18. Mahley R.W., Bersot T.P. Drug therapy for hypercholesterolemia and dyslipidemia. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2006, 933-966. McGraw-Hill, New York. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
19. Paoletti R., Corsini A., Bellosta S. Pharmacological interactions of statins. Atherosclerosis Suppl 2002, 3:35-40.
20. Tong J., Laport G., Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant 2005, 36:739-740.